Webinar

How to avoid the 5 most relevant inspection findings related to the QPPV

Required by the European Union, the Qualified Person Responsible for Pharmacovigilance (QPPV) is critical to product compliance and marketing authorization in Europe. Many companies, however, are struggling to manage the evolving role of the QPPV to support growth in these important markets – resulting in inspection findings that add time, cost, and risk to marketed products. Watch the on-demand webinar with our QPPV experts, Monica Buchberger and Susanne Becker, as they discussed managing QPPVs for companies from the US, Europe, Japan, and other markets.

Key learnings

  • Examine why the QPPV role is critical to avoid risk and delays in marketing authorizations
  • Share the root causes behind the most common QPPV-related inspection findings, and how to identify and correct them early
  • Review best practices for oversight by the QPPV role over regional and local affiliate safety operations, without burdening safety teams
  • Discuss how innovative technologies are making it easier for companies to monitor KPIs and adherence to SLAs when outsourcing the QPPV to specialized providers
  • Assess the impact of the recently revised Implementing Regulation in the EU on QPPVs 
Business meeting

Access the recording

Pardot Form

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Related resources

Article

Harnessing AI and advanced analytics to revolutionize PV signal management

Article

The growing case for AI to support pharmacovigilance: World Drug Safety Congress Americas key takeaways

Article

Five frequent inspection findings and the role of the QPPV